share_log

Returns On Capital At Surgery Partners (NASDAQ:SGRY) Have Hit The Brakes

Returns On Capital At Surgery Partners (NASDAQ:SGRY) Have Hit The Brakes

Surgery Partners(纳斯达克股票代码:SGRY)的资本回报率已经停滞不前
Simply Wall St ·  03/27 06:30

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. However, after briefly looking over the numbers, we don't think Surgery Partners (NASDAQ:SGRY) has the makings of a multi-bagger going forward, but let's have a look at why that may be.

我们应该寻找哪些趋势?我们想确定可以长期价值成倍增长的股票?理想情况下,企业将表现出两种趋势;首先是增长 返回 论资本使用率(ROCE),其次是增加 金额 所用资本的比例。这向我们表明,它是一台复合机器,能够持续将其收益再投资到业务中并产生更高的回报。但是,在简短地研究了这些数字之后,我们认为Surgery Partners(纳斯达克股票代码:SGRY)在未来不具备多袋装机的实力,但让我们来看看为什么会这样。

Understanding Return On Capital Employed (ROCE)

了解资本使用回报率 (ROCE)

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. Analysts use this formula to calculate it for Surgery Partners:

如果你以前没有与ROCE合作过,它会衡量公司从其业务中使用的资本中产生的 “回报”(税前利润)。分析师使用以下公式来计算手术合作伙伴的利润:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

已动用资本回报率 = 息税前收益 (EBIT) ¥(总资产-流动负债)

0.065 = US$415m ÷ (US$6.9b - US$523m) (Based on the trailing twelve months to December 2023).

0.065 = 4.15亿美元 ÷(69亿美元-5.23亿美元) (基于截至2023年12月的过去十二个月)

Therefore, Surgery Partners has an ROCE of 6.5%. Ultimately, that's a low return and it under-performs the Healthcare industry average of 11%.

因此,Surgery Partners的投资回报率为6.5%。归根结底,这是一个低回报,其表现低于医疗保健行业11%的平均水平。

roce
NasdaqGS:SGRY Return on Capital Employed March 27th 2024
纳斯达克GS:SGRY 2024年3月27日动用资本回报率

Above you can see how the current ROCE for Surgery Partners compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Surgery Partners for free.

上面你可以看到Surgery Partners当前的投资回报率与其先前的资本回报率相比如何,但从过去可以看出来的只有那么多。如果你愿意,你可以免费查看涵盖外科合作伙伴的分析师的预测。

So How Is Surgery Partners' ROCE Trending?

那么手术伙伴的投资回报率趋势如何呢?

In terms of Surgery Partners' historical ROCE trend, it doesn't exactly demand attention. The company has employed 47% more capital in the last five years, and the returns on that capital have remained stable at 6.5%. Given the company has increased the amount of capital employed, it appears the investments that have been made simply don't provide a high return on capital.

就Surgery Partners的历史投资回报率趋势而言,这并不完全值得关注。在过去五年中,该公司雇用的资本增加了47%,该资本的回报率一直稳定在6.5%。鉴于该公司增加了动用资本金额,看来已经进行的投资根本无法提供很高的资本回报率。

The Bottom Line

底线

As we've seen above, Surgery Partners' returns on capital haven't increased but it is reinvesting in the business. Investors must think there's better things to come because the stock has knocked it out of the park, delivering a 146% gain to shareholders who have held over the last five years. Ultimately, if the underlying trends persist, we wouldn't hold our breath on it being a multi-bagger going forward.

正如我们在上面看到的那样,Surgery Partners的资本回报率没有增加,但它正在对业务进行再投资。投资者一定认为会有更好的事情发生,因为该股已经脱颖而出,为在过去五年中持股的股东带来了146%的收益。归根结底,如果潜在的趋势持续下去,我们就不会屏住呼吸了,因为它是未来的 “多管齐下”。

On a separate note, we've found 1 warning sign for Surgery Partners you'll probably want to know about.

另一方面,我们为你可能想知道的手术伙伴找到了一个警告标志。

While Surgery Partners isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

尽管Surgery Partners的回报率并不高,但请查看这份免费清单,列出了资产负债表稳健的股本回报率高的公司。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发